Skip to main content
Roohi Ismail-Khan, MD, Oncology, Indianapolis, IN

RoohiIsmail-KhanMDMSC

Oncology Indianapolis, IN

Breast Cancer, Gynecologic Cancer

Associate VP, Lilly Oncology

Dr. Ismail-Khan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ismail-Khan's full profile

Already have an account?

  • Office

    893 Delaware Street
    Indianapolis, IN 46225
    Phone+1 813-340-2252

Summary

  • Roohi Ismail-Khan, MD, is an experienced oncologist based in Tampa, FL. She specializes in breast cancer, Gyn cancer, cardio-oncology, and clinical research. She completed her education and fellowship at the University of South Florida and Moffitt Cancer Center. She had a long clinical career at Moffitt in Breast Cancer, Gyn Cancer, and Cardio-Oncology. She completed her MSc in Clinical Research at USF. She now works in Global Drug Development at Eli Lilly Oncology as an Associate VP in Medical Oncology. She has an extensive record of publication in oncology and her clinical trial work focuses largely on breast cancer. Dr. Ismail-Khan is widely recognized in her field, garnering honors such as the Patient's Choice Award, Most Compassionate Doctor, and the "Physician of the Year" Award from Moffitt Cancer Center. She was recently awarded the prestigious LRL Presidential Award for her work in championing Diversity and Inclusion in Clinical Trials.

Education & Training

  • University of South Florida
    University of South FloridaM.S.M.S., Clinical and Translational Research, Cum Laude, 2006 - 2010
  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2005 - 2007
  • University of South Florida Morsani
    University of South Florida MorsaniResidency, Internal Medicine, 2001 - 2004
  • St. George's University School of Medicine
    St. George's University School of MedicineClass of 2000
  • Wesleyan College
    Wesleyan CollegeBSc, Biology/Psychology/English, Summa Vum Laude, 1991 - 1995

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2005 - 2025

Awards, Honors, & Recognition

  • LRL President’s Award Eli Lilly and Company, 2022
  • Patient's Choice Award 2014, 2015 Vitals, 2015-2016
  • Most Compassionate Doctor Vitals, 2014-2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Beta-catenin Expression Patterns in Matched Pre and Post Neoadjuvant Chemotherapy Resistant Breast Cancer  
    Rosa M, Han HS, Ismail-Khan R, Allam-Nandyala P, Bui M, Annals of Clinical and Laboratory Science, 1/1/2015
  • A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors  
    Soliman HH, Jackson E, Neuger T, Dees C, Harvey D, Han H, Ismail-Khan R, Minton SE, Vahanian N, Link C, Sullivan D, Antonia S, Oncotarget, 1/21/2014
  • Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estro...  
    Yardley D, Ismail-Khan R, Trepel J, et al, Journal Of Clinical Oncology, 1/6/2013
  • Join now to see all

Abstracts/Posters

  • A Phase II, open label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)
    Bardia A, Kummel S, Garcia-Estevez L, Huang CS, Cortes Castan J, Ruiz Borrego M, Telli ML, Lluch Hernandez A, Lopez R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz S, Maye..., ASCO, Chicago, IL, 1/1/2015
  • The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple negative breast cancer clinical development and cli...
    Marchion DC, Xiong Y, Ismail-Khan R, Abbasi F, Bou Zgheib N, Ramirez IJ, Bush SH, Hakam A, Judson PL, Lancaster JM, SGO 45th Annual Meeting, Tampa, FL, 1/21/2014
  • AKT survival signaling and phospho-AKT expression are associated with triple negative breast cancer development and clinical outcome
    Marchion DC, Ismail-Khan R, Abbasi F, Boac B, Xiong Y, McClung C, Khulpateea BR, Bush SH, Hakam A, Lancaster JM, SGO 45th Annual Meeting, Tampa, FL, 1/21/2014
  • Join now to see all

Lectures

  • Cardiac Complications from Chemotherapy and The New Cardio-Oncology Program 
    1/12/2015
  • Issues in Breast Cancer Therapy 
    University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL - 1/1/2015
  • Triple Negative breast cancer 
    1/1/2015
  • Join now to see all

Other

  • Cardio-Oncology: An Important New Specialty to Improve Patient Outcomes 
    Ismail-Khan R and Fradley M
    University of South Florida and Moffitt Cancer Center - 1/1/2015
  • Triple Negative Breast Cancer 
    Ismail-Khan R, International Hospital and Equipment (IHE), PanGlobal Media
    1/1/2010
  • Why Focus on Triple Negative Breast Cancer? 
    Ismail-Khan R, Factors Publications

Press Mentions

  • Research Report
    Research ReportSeptember 28th, 2020
  • Perspectives: The Benefit of Cardio- Oncology Programs for Cancer Patients
    Perspectives: The Benefit of Cardio- Oncology Programs for Cancer PatientsSeptember 28th, 2020
  • Moffitt Cancer Center Takes Whole-Patient Treatment to Heart
    Moffitt Cancer Center Takes Whole-Patient Treatment to HeartSeptember 28th, 2020
  • Join now to see all

Professional Memberships

Other Languages

  • Urdu, Hindi, Spanish